The most common type of PET scan, called FDG-PET, appears to lead to the best therapy for patients who have a newer diagnosis of non-small cell lung cancer and in those who have undergone treatment for Hodgkin's lymphoma. FDG-PET can also help identify the best treatment for patients with colorectal cancer, and it can detect small, potentially malignant lung growths called solitary pulmonary nodules, according to the review authors led by Karen Facey ("Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers" - Health Technology Assessment 11(44), 2007.
"For other cancers, PET can often improve the accuracy of detecting a tumour, but it is unclear how this affects a patient's treatment and ultimately their outcome", stated Karen Facey, an evidence-based health policy researcher. The most reliable evidence "would suggest that FDG-PET is cost-effective in the United Kingdom in non-small cell lung cancer and Hodgkin's lymphoma", she added.
Karen Facey noted that this is the first comprehensive review of PET for determining how well patients are responding to chemotherapy and for determining the sites for radiation therapy. "It has identified many interesting new studies, but these are difficult to interpret given their different designs, so there's a real need for larger, better quality studies of this kind to be performed in the United Kingdom", she stated.
The review is published in the latest issue of Health Technology Assessment, the international journal series of the Health Technology Assessment (HTA) programme, part of the National Institute for Health Research in the United Kingdom.
Karen Facey and colleagues combed through the results of six systematic reviews and 158 primary studies that examined the effect of PET scans on the management of breast, colorectal, head and neck, lung, lymphoma, melanoma, esophageal and thyroid cancers.
For instance, did PET scans diagnose these cancers better than an MRI or CT scan? Could a PET scan give a better idea of a cancer's severity or spread? Would they be better than other imaging techniques at detecting the recurrence of a cancer or monitoring a tumour's response to treatment? For many of the cancers examined in the review, the answers are still inconclusive and require larger, more careful study, the HTA authors found.
While research continues, physicians are already using combination PET/CT scans to help diagnose and treat cancer patients. Karen Facey and colleagues also reviewed this new technology and stated that the PET/CT scans appear to be "slightly more accurate" so far.
In September 2007, the Society of Nuclear Medicine, whose members use PET technology, updated its "scope of practice" guidelines to reflect this trend. "Since many of the state-of-the-art nuclear medicine cameras as well as PET scanners have CT scanners attached to them, performing CT scans becomes one of the nuclear medicine technologist's tasks", stated Cindi Luckett-Gilbert, the chair of the society's special task force on the scope of practice.
The HTA programme is part of the National Institute for Health Research and produces high quality research information about the effectiveness, costs and broader impact of health technologies, with more than 450 projects published since its inception. About 50 are published each year, all available for free download. It is co-ordinated by the National Co-ordinating Centre for Health Technology Assessment, based at the University of Southampton.